Integrated DNA Technologies, Inc. et al. v. Tecan Group AG

Eunsung Global Corp.vsHydraFacial LLC et al.

Eunsung Global Corp. and HydraFacial LLC settled their inter partes review disputes, leading the PTAB to terminate both IPRs before institution. The settlement agreement is treated as confidential business information.

Google LLCvsSecure Communication Technologies, LLC

The PTAB held that claims 19‑23 of the ’592 patent were obvious over Perttila and Insolia and thus unpatentable, while claims 25, 26, 28, 29 remained patentable. The decision reflects a mixed outcome for the parties.

Ecto World, LLC d/b/a Demand Vape et al.vsRAI Strategic Holdings, Inc. et al.

RAI Strategic Holdings defends its ’202 patent against Demand Vape's IPR challenge, asserting the Board correctly applied Advanced Bionics precedent and that Fintiv factors favor denial due to an overlapping ITC case.

Tesla, Inc.vsIntellectual Ventures II

Tesla has filed an IPR petition seeking cancellation of all eight claims of Intellectual Ventures II’s ’889 patent covering closed‑loop power control in CDMA/3G networks. The challenger argues the claims are obvious over the Dateki patent, the Mate publication, and the Chitrapu publication, which disclose the same F‑DPCH mechanisms before the patent’s priority date.

3Shape A/S et al.vsMedit Corporation et al.

3Shape and Medit settled their inter partes review dispute over patent 9,262,864 B2. The parties jointly moved to terminate the IPRs, and the Board granted the motion, dismissing the petitions and keeping the settlement confidential.